Drug class
Pegylated interferon alfa; recombinant cytokine immunomodulator and antiviral agent
Mechanism of action
A covalent conjugate of recombinant interferon alfa and polyethylene glycol. Binding to cell-surface interferon receptors triggers JAK-STAT signalling and transcription of interferon-stimulated genes, producing antiviral, antiproliferative and immunomodulatory effects. PEG conjugation reduces clearance and prolongs systemic exposure.
General use cases
- The term peginterferon covers multiple subtype-specific products (for example peginterferon alfa-2a and alfa-2b) with distinct labels. Depending on the subtype and product, indications have included chronic hepatitis B or C and selected myeloproliferative neoplasms; use the exact peginterferon product label for clinical indications.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
